Healthcare: Why Investors Just Doubled Their Money on This Stock

<p><span style="font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 16px;">Alexion Pharmaceuticals is paying $8.4 billion to buy Synageva, a company without any sales, so Fool analyst Michael Douglass and contributor Todd Campbell are digging into this deal to see what it may mean to biotech investors.</span></p>